Ocrelizumab-Induced Brain Volume Dynamics in Relapsing-Remitting Multiple Sclerosis. De Masi R, Orlando S Pharmaceuticals (Basel). 2026 May 25; 19(6). PMID: 42356446. Abstract CommentRecommendBookmarkWatch